At today's price, Pfizer's stock is pricing in roughly 7.8% to 9.6% annual free-cash-flow growth for the next ten years, depending on the FCF base used — a number that can't be meaningfully judged against Pfizer's own 5-year track record, since both the 2021-2022 COVID boom and the 2023 crash that followed are too distorted to serve as a fair comparison.
At its current price, PFE implies ~7.8% annual FCF growth for the next 10 years (FY2025 FCF base, WACC 9%) — or ~9.6% using a 3-year-average FCF base instead.
Pfizer's 5-year FCF growth (2021→2025) was -25.8% a year — but that figure is too distorted by the COVID vaccine boom and its collapse to be a meaningful comparison point.
Required growth vs. historical growth
Required growth from the reverse DCF below. The 5-yr and 2-yr historical CAGRs bracket wildly different figures precisely because neither 2021-2022 (COVID peak) nor 2023 (COVID trough) is a normal baseline year — both are shown for completeness, not as a reliable growth signal.
Sensitivity: what if the discount rate moves?
| WACC | Required growth (FY2025 FCF base) | Required growth (3-yr avg FCF base) |
|---|---|---|
| 7% | 2.9% | 4.6% |
| 9% (base case) | 7.8% | 9.6% |
| 11% | 11.9% | 13.8% |
Pfizer is a large, S&P 500 pharmaceutical company, so a 9% discount rate was used as the base case. Moving the discount rate by just 2 percentage points in either direction roughly doubles the gap in required growth — this result is unusually sensitive to that single assumption.
What would move this number
- Switching the FCF base from FY2025's single-year figure ($9,075M) to the 3-year average ($7,901M) raises the required growth rate from 7.8% to 9.6% at WACC 9% — a smaller base requires faster growth to reach the same target value. FY2025's FCF was used as the primary base here since it fell within this site's ±40% normalization threshold relative to the 3-year average (+14.9%).
- Lowering the discount rate to 7% drops the required growth to as low as 2.9%; raising it to 11% pushes it up to 11.9%.
- How net debt is measured also matters — this analysis used total borrowings ($64.8B) minus cash and short-term investments ($13.6B), for net debt of about $51.2B. Pension obligations and litigation reserves were not included.
Show your work
Inputs, sources, model assumptions, and the calculation
- Share price$28.55 — Investing.com, Sept 2, 2026 close
- Shares outstanding5,686,267,431 — 10-K FY2025 cover page, as of Feb 19, 2026
- Market cap≈$162.3B — price × shares (calculated)
- Total debt$64,795M — short-term borrowings $3,154M + long-term debt $61,641M, 10-K FY2025 p.53
- Cash and short-term investments$13,596M — cash $1,142M + short-term investments $12,454M, 10-K FY2025 p.53
- Net debt$51,199M — total debt minus cash and short-term investments (calculated)
- FCF (FY2025)$9,075M — operating cash flow $11,704M minus capex $2,629M, 10-K FY2025 p.59
- FCF, 3-year average (2023-2025)$7,901M — FY2025 is +14.9% above this average, within this site's ±40% normalization threshold, so used as-is without adjustment (3-year average shown as an alternate scenario)
- Discount rate (WACC)9% base case (7%/11% tested)
- Terminal growth rate2.5% — long-run GDP-level assumption
Model: free cash flow is assumed to grow at a constant annual rate g for 10 years, then at a 2.5% terminal rate thereafter, solved by bisection for the value of g that equates present value to today's enterprise value (market cap plus net debt, ≈$213.5B).
Historical CAGR check: 5-yr FCF CAGR (2021→2025) = -25.8%, distorted by the COVID vaccine/treatment boom (2021-2022) and its collapse (2023). 2-yr recovery FCF CAGR (2023→2025, off the 2023 trough) = +37.6%, also distorted by the unusually low 2023 base.
The fine print
- This isn't a fair-value price target — it only shows what the current price already assumes.
- Change the discount rate or the FCF base, and the answer moves substantially — see the sensitivity table above.
- Whether 7.8-9.6% growth is realistic depends almost entirely on whether new products can offset the ~40% of revenue facing 2026-2029 patent expirations — not on this math alone.
- A reverse DCF shows what the market currently expects — it does not say what the stock is "worth."
- Any investment decision, and its outcome, is your own responsibility.
Frequently asked questions
What growth rate does PFE's stock price assume?
At today's price, Pfizer's stock is pricing in about 7.8% annual free-cash-flow growth for the next ten years using FY2025's FCF as the base (at a 9% discount rate), or 9.6% if a 3-year-average FCF base is used instead.
Can Pfizer's historical growth tell us whether that's realistic?
Not reliably. Pfizer's 5-year FCF CAGR (2021→2025) is -25.8%, but 2021-2022 were inflated by COVID vaccine and treatment sales, and 2023 was an artificially depressed trough as that demand collapsed. Neither end of that comparison is a fair baseline, which is why this analysis leans on the patent-cliff picture instead.
What share price was used for this analysis?
This analysis used $28.55, as of the Sept 2, 2026 close.